Committees

Several committees oversee EORTC’s strategy and independence as well as the relevance and scientific value of all research efforts, ensuring scientific work is of the highest possible quality. Each EORTC committee chair is elected to serve a three-year term which may be renewed upon recommendation by the EORTC Board.

Protocol Review Committee

The Protocol Review Committee (PRC), which is appointed by the EORTC Board, comprises experts in all disciplines of oncology, 50% of whom are not EORTC members. In addition, the PRC makes systematic use of external reviewers – a minimum of three international experts are consulted for each outline, providing an independent review.

The PRC reviews and approves all research projects proposed by EORTC groups. The Translational Research Advisory Committee (TRAC) provides additional scientific expertise when needed. The New Drug Advisory Committee (NDAC) supports the evaluation of new molecules incoming in the EORTC.

  • R. Schilsky - Alexandria, US

    Chair

    American Society of Clinical Oncology

  • M. Eriksson - Lund, SE

    Vice-Chair

    Skane University Hospital

  • F. Alongi - Verona, IT

    Member

    Sacro Cuore Hospital

  • F. Baron - Liège, BE

    Member

    C.H.U. Sart-Tilman

  • A. Beer - Ulm, DE

    Member

    Universitaetsklinikum Ulm

  • L. Blomqvist - Stockholm, SE

    Member

    Karolinska University Hospital, location Solna

  • S. Bodis - Aarau, CH

    Member

    Kantonsspital Aarau

  • F. Brunotte - Dijon, FR

    Member

    Centre Georges-Francois-Leclerc

  • A. Chiti - Milano, IT

    Member

    Istituto Clinico Humanitas

  • K. Conlon - Dublin, IE

    Member

    Trinity College - University Of Dublin

  • A. Craft - Newcastle-Upon-Tyne, GB

    Member

    Newcastle Hospitals NHS Trust - Royal Victoria Infirmary

  • V. Dieras - Paris, FR

    Member

    Institut Curie

  • M. Guckenberger - Zurich, CH

    Member

    UniversitaetsSpital Zurich

  • P. Goodwin - Toronto, CA

    Member

    Mount Sinai Hospital

  • E. Haglind - Goteborg, SE

    Member

    Sahlgrenska Universitetssjukhuet

  • P. Hoskin - Northwood, GB

    Member

    East and North Hertfordshire NHS Trust – Mount Vernon Hospital

  • N. Isambert - Dijon, FR

    Member

    Centre Georges-Francois-Leclerc

  • A. Jimeno - Denver, US

    Member

    University Of Colorado Cancer Center

  • S. Mandrekar - Rochester, US

    Member

    Mayo Clinic

  • G. Marcucci - Duarte, US

    Member

    City Of Hope National Medical Center

  • S. Michiels - Villejuif, FR

    Member

    Gustave Roussy

  • O. Nielsen - Aarhus, DK

    Member

    Aarhus University Hospital

  • J. Oliveira - Lisboa, PT

    Member

    I.P.O. Francisco Gentil - Centro De Lisboa

  • M. Redman - Seattle, US

    Member

    Fred Hutchison Seattle Cancer Care Alliance

  • J. Rodon - Barcelona, ES

    Member

    Hospital General Vall D'Hebron

  • F. Shepherd - Toronto, CA

    Member

    University Health Network - Oci / Princess Margaret Hospital

  • A. Sobrero - Genova, IT

    Member

    Ospedale San Martino / Cliniche Universitarie Convenzionale

  • M. Sydes - London, GB

    Member

    MRC Clinical Trials Office

  • G. Velikova - Leeds, GB

    Member

    Leeds Teaching Hospitals NHS Trust - St. James's University Hospital

  • A. Elias - Denver, US

    Phase I-II PRC Expert

    University Of Colorado Cancer Center

  • H. Hirte - Hamilton, CA

    Phase I-II PRC Expert

    Hamilton Health Sciences, Juravinski Cancer Centre

  • I. Judson - London, GB

    Phase I-II PRC Expert

    The Royal Marsden Hospital

  • P. O'Dwyer - Philadelphia, US

    Phase I-II PRC Expert

    University Of Pennsylvania - Presbyterian Medical Center

  • W. Parulekar - Kingston, CA

    Phase I-II PRC Expert

    CCTG - Queen'S University

  • D. Ross Camidge - Denver, US

    Phase I-II PRC Expert

    University Of Colorado Cancer Center

  • L. Siu - Toronto, CA

    Phase I-II PRC Expert

    University Health Network - Oci / Princess Margaret Hospital

  • D. Lacombe - Brussels, BE

    Ex-Officio Member

    EORTC Headquarters

View moreView less

Independent Data Monitoring Committee

The Independent Data Monitoring Committee (IDMC) conducts interim reviews of EORTC studies and intergroup studies where the EORTC is the coordinating group (including studies done in partnership with the pharmaceutical industry).

The IDMC will make recommendations on whether or not to pursue or adapt a clinical trial based on scientific, ethical, statistical or safety considerations.

  • M. Mason - Cardiff, GB

    Chair

    Velindre NHS Trust - Velindre Cancer Centre

  • J. Armand - Villejuif, FR

    Member

    Gustave Roussy

  • H. Bartelink - Amsterdam, NL

    Member

    The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis

  • G. Griffiths - Southampton, GB

    Member

    Southampton Clinical Trials Unit, University of Southampton

View moreView less

The permanent IDMC for EORTC studies functions according to a Charter and a policy.

All communication with the IDMC should be addressed in writing to IDMCsec@eortc.be.

New Drug Advisory Committee

The New Drug Advisory Committee (NDAC) acts as a reference body for all EORTC groups, and makes recommendations to them on all aspects of drug development, including selecting the most promising compounds.

The committee focuses on molecules that have not been registered or are not already used in oncology. Working closely with the Early Project Optimisation Department within EORTC, NDAC helps design of clinical studies evaluating these treatments, advises the Board on project reviews and makes connections with industry partners.

  • J. Bizzari - Haverford, US

    Chair

  • A. Astier - Paris, FR

    Member

    Assistance Publique - Hopitaux de Paris - CHU Henri Mondor

  • A. Awada - Brussels, BE

    Member

    Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet

  • U. Banerji - Sutton, GB

    Member

    Royal Marsden Hospital

  • J. Dancey - Kingston, CA

    Member

    CCTG - Queen'S University

  • K. Dhingra - Sparta, US

    Member

  • J. Martens - Rotterdam, NL

    Member

    Erasmus MC

  • G. Peters - Amsterdam, NL

    Member

    VU University Medical Center

  • J. Tabernero - Barcelona, ES

    Member

    Hospital General Vall D'Hebron

  • N. Harbeck - Munich, DE

    Ex Officio member

    Klinikum der Universitaet Muenchen - Campus Grosshadern

  • S. Tejpar - Leuven, BE

    Ex Officio member

    U.Z. Leuven - Campus Gasthuisberg

View moreView less

Scientific Audit Committee

The EORTC Scientific Audit Committee (SAC) gives independent advice to the EORTC Board on the activities, scientific output, overall priorities and strategies of the EORTC. The SAC evaluates the effectiveness of research programmes and makes suggestions to strengthen the EORTC’s overall functioning. The committee’s members represent a cross-section of international opinion leaders and experts, half of whom have no other EORTC involvement.

  • E. Eisenhauer - Kingston, CA

    Chair

    Queen’s University

  • J. Pierga - Paris, FR

    Secretary

    Institut Curie

  • J. De Bono - Sutton, GB

    Member

    Royal Marsden Hospital

  • L. Ellis - Houston, US

    Member

    MD Anderson Cancer Center

  • C. Grau - Aarhus , DK

    Member

    Aarhus University Hospital

  • D. Lacombe - Brussels, BE

    Member

    EORTC Headquarters

  • P. Ljungman - Stockholm, SE

    Member

    Karolinska University Hospital , location Huddinge

  • K. Margolin - Seattle, US

    Member

    Fred Hutchison Seattle Cancer Care Alliance

  • J. Radford - Manchester, GB

    Member

    The Christie NHS Foundation Trust

  • E. Rutgers - Amsterdam, NL

    Member

    The Netherlands Cancer Institute
    Antoni van Leeuwenhoekziekenhuis

  • E. Voest - Amsterdam, NL

    Member

    Netherlands Cancer Institute (NKI)

  • J. Jassem - Gdansk, PL

    Member

    Medical University Of Gdansk

View moreView less

Quality Assurance Committee

The primary objective of the Quality Assurance Committee (QAC) is to ensure compliance with Good Clinical Practice and new directives/guidelines from Regulatory Authorities, assessing potential serious non-compliance issues and recommending corrective actions. In addition, the committee recommends ways to develop and continuously improve transversal quality assurance strategies and initiatives in transversal fields such as radiotherapy, surgery and pathobiology.

New Chair to be appointed.

  • C. de Balincourt - Brussels, BE

    Secretary

    EORTC Headquarters

  • C. Coens - Brussels, BE

    Member

    EORTC Headquarters

  • M. den Dulk - Maastricht, NL

    Member

    Academisch Ziekenhuis Maastricht

  • P. Hau - Regensburg, DE

    Member

    Universitaetskliniken Regensburg

  • B. Kasper - Mannheim, DE

    Member

    Mannheim University Medical Center

  • D. Lacombe - Brussels, BE

    Member

    EORTC Headquarters

  • L. Licitra - Milano, IT

    Member

    Fondazione IRCCS, Istituto Nazionale dei Tumori

  • J. Machiels - Brussels, BE

    Member

    Cliniques Universitaires Saint-Luc

  • R. Salgado - Brussels, BE

    Member

    Breast Cancer Translational Research Laboratory

  • M. Spahn - Bern, CH

    Member

    Inselspital

  • D. Weber - Villigen, CH

    Member

    Paul Scherrer Institute - Center for Proton Therapy (CPT)

View moreView less

Translational Research Advisory Committee

The Translational Research Advisory Committee (TRAC) provides expert advice on translational research projects conducted within the EORTC and stimulates new translational research trials using existing clinically-annotated biosamples. TRAC comprises permanent and ex officio members representing all the main disciplines of translational research in oncology.

  • S. Tejpar - Leuven, BE

    Chair

    U.Z. Leuven - Campus Gasthuisberg

  • M. Daidone - Milano, IT

    Vice-Chair

    Fondazione IRCCS Istituto Nazionale dei Tumori

  • H. Allgayer - Mannheim, DE

    Member

    UniversitaetsMedizin Mannheim

  • N. Bruenner - Copenhagen, DK

    Member

    University of Copenhagen-Lifepharm Center

  • M. Callari - Cambridge , GB

    Member

    Cruk Cambridge Institute

  • F. Cardoso - Lisbon, PT

    Member

    Champalimaud Cancer Center

  • N. deSouza - Sutton, GB

    Member

    Royal Marsden Hospital Sutton

  • S. Eppenberger - Basel, CH

    Member

    University Hospital Basel

  • C. Fink - Celle, DE

    Member

    Allgemeines Krankenhaus Celle

  • T. Gevaert - Leuven, BE

    Member

    Catholic University Leuven

  • R. Giavazzi - Bergamo, IT

    Member

    Laboratori Of Biology Mario Negri Institute

  • M. Hegi - Lausanne, CH

    Member

    Laboratory of Brain Tumor Biology and Genetics – CHUV

  • R. Iggo - Bordeaux, FR

    Member

    Institut Bergonie - Laboratoire De Biochimie

  • T. Turnsek - Ljubljana, SI

    Member

    National Institute of Biology

  • P. Lambin - Maastricht , NL

    Member

    Maastro Clinic - Maastricht Radiation Oncology

  • J. Martens - Rotterdam, NL

    Member

    Erasmus MC

  • S. Michiels - Villejuif, FR

    Member

    Gustave Roussy

  • F. Mottaghy - Aachen, DE

    Member

    Universitätsklinikum Aachen AÖR - Medizinische Fakultät der RWTH

  • K. Pantel - Hamburg, DE

    Member

    Universitaets-Krankenhaus Eppendorf

  • P. Perego - Milano, IT

    Member

    Istituto Nazionale dei Tumori di Milano

  • G. Peters - Amsterdam, NL

    Member

    VU University Medical Center

  • A. Rhodes - Bristol, GB

    Member

    The University of the West of England - Frenchay Campus

  • E. Rouleau - Paris, FR

    Member

    Institut Gustave Roussy

  • R. Salgado - Brussels, BE

    Member

    Breast Cancer Translational Research Laboratory

  • I. Skvortsova - Innsbruck, AT

    Member

    Innsbruck Universitaetsklinik

  • P. Span - Nijmegen, NL

    Member

    Radboud University Medical Center Nijmegen

  • F. Sweep - Nijmegen, NL

    Member

    Radboud University Medical Center Nijmegen

  • G. Van den Eynden - Brussels, BE

    Member

    Institut Jules Bordet, GasthuisZustersAntwerpen

  • L. Van Kempen - Montreal, CA

    Member

    Jewish General Hospital

  • N. Zaffaroni - Milano, IT

    Member

    Fondazione IRCCS Istituto Nazionale dei Tumori

  • J. Bizzari - Haverford, US

    Ex Officio member

View moreView less

Membership Committee

The Membership Committee assesses the qualifications and expertise available at research institutions and coordinates their affiliation with the EORTC network.

  • A. Marinus - Brussels, BE

    Secretary

    EORTC Headquarters

  • T. Conroy - Vandoeuvre-Les-Nancy, FR

    Member

    Institut de Cancérologie de Lorraine

  • M. Groenvold - Copenhagen, DK

    Member

    Bispebjerg Hospital

  • E. Lartigau - Lille, FR

    Member

    Centre Oscar Lambret

  • J. Vermorken - Edegem, BE

    Member

    Universitair Ziekenhuis Antwerpen

View moreView less

Institutional Review Board

EORTC’s Institutional Review Board (IRB) is responsible for safeguarding the rights and welfare of those participating in clinical trials it supports. This includes protecting the privacy and confidentiality of patient data and validating informed consent and patient information document templates. All institutions and investigators submitting data to the body’s headquarters agree to abide by the decisions of the IRB regarding data collection, transfer, storage, release, retention, and disposition, as these pertain to individual patient privacy and confidentiality. The IRB also reviews potential conflicts of interest reported to headquarters.

  • A. Negrouk - Brussels, BE

    Chair

    EORTC Headquarters

  • F. Crawley - Antwerp, BE

    Member

    Good Clinical Practice Alliance

  • C. de Balincourt - Brussels, BE

    Member

    EORTC Headquarters

  • C. Fortpied - Brussels, BE

    Member

    EORTC Headquarters

  • J. Geissler - Munich, DE

    Member

    European Patients' Academy on Therapeutic Innovation

  • J. Otten - Brussels, BE

    Member

    Universitair Ziekenhuis Brussel

  • P. Ruyskart - Brussels, BE

    Member

    EORTC Headquarters

View moreView less